Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma

Naohiro Nishida, Makoto Yamsaki, Kazuki Odagiri, Kotaro Yamashita, Koji Tanaka, Daisuke Sakai, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Taroh Satoh, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background/Aim: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. Patients and Methods: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. Results: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). Conclusion: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.

Original languageEnglish
Pages (from-to)2249-2254
Number of pages6
JournalIn Vivo
Volume33
Issue number6
DOIs
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this